Navigation Links
Professor collaborates on most comprehensive analyses of NSAIDs and coxibs
Date:5/30/2013

Charles H. Hennekens, MD, DrPH, the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published in the current issue of the Lancet the most comprehensive analyses of the benefits and risks of non-steroidal anti-inflammatory drugs (NSAIDs), which include cyclo-oxygenase-2 inhibitors (coxibs).

Hennekens and colleagues from around the world, under the direction of the Clinical Trial Service and Epidemiology Studies Unit at the University of Oxford, conducted a world-wide meta-analyses using individual participant data from 280 trials of NSAIDs vs. placebo and 474 trials of NSAID vs. another NSAID, which involved a total of 353,809 participants and a total of 233,798 person-years. These results address risks and benefits of drugs used for relief of inflammatory arthritis including cardiovascular disease and other relevant outcomes such as gastrointestinal effects.

"The vascular risks of high-dose diclofenac and ibuprofen are comparable to coxibs, while high-dose naproxen is associated with less vascular risk than other NSAIDs," said Hennekens. "Although NSAIDs increase vascular and gastrointestinal risks, their magnitude can be predicted, which may help guide clinical decision-making."

David J. Bjorkman, MD, MSPH, dean of the Charles E. Schmidt College of Medicine at FAU and a gastroenterologist noted that "these are the most comprehensive analyses ever conducted of the benefits and risks of NSAIDs, which include coxibs, and should help guide healthcare providers in their prescribing patterns."

Hennekens concluded that "from a clinical and policy perspective, the available data suggest that for relief of pain of inflammatory arthritis, naproxen may have the best benefit-to-risk ratio on cardiovascular disease (CVD). In contrast to naproxen, other traditional NSAIDS and coxibs confer similar moderately increased risks of CVD. At present, individual clinical judgments about coxibs and nonselective NSAIDs should not be limited to risks of CVD. They should also include concerns about non-CVD risks, such as gastrointestinal bleeding and other benefits, including improved quality of life resulting from decreases in impairment from musculoskeletal pain syndromes."

Science Watch ranked Hennekens as the third most widely cited medical researcher in the world from 1995-2005, and five of the top 20 were his former trainees and/or fellows. In addition, in 2012 Science Heroes, ranked Hennekens No. 81 in the history of the world for having saved more than 1.1 million lives.


'/>"/>

Contact: Gisele Galoustian
ggaloust@fau.edu
561-985-4615
Florida Atlantic University
Source:Eurekalert

Related medicine news :

1. Louisiana Tech University professor earns NSF Early Career Development grant
2. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
3. Louisiana Tech biomedical engineering professor earns recognition, funding for research
4. Women professorships low in some Scandinavian universities due to sexism
5. President Obama names SF State math professor a top young scientist
6. From textbook to flexbook: Professor uses new collaborative tool in the classroom
7. IHME professor named first health measurement winner of prestigious innovation award
8. Guys, take note: Male birth control pill may be ready soon, says Texas A&M professor
9. UBC professor wins Canadas top pharmaceutical research award
10. Huddersfield professors ground-breaking research shows just how well the 2012 Games were run
11. Grove Professor receives $1.5MM to study breast cancer therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... ... announced today the introduction of the innovative newly improved Iso-Hip Wrap. The ... patients. The plush design enhances comfort and enables the patient to enjoy the ...
(Date:5/4/2016)... ... ... Nike Rugby Camp's success is due in large part to Ethan Willis ... Camps and current Nike Camp director, has offered an all abilities rugby camp staffed ... for our eighth summer here in San Diego,” says Willis. "We take great pride ...
(Date:5/4/2016)... LA (PRWEB) , ... May 04, 2016 , ... Hight-Doland ... LA area has teamed up with Big Brothers Big Sisters of Southwest Louisiana to ... being accepted here . , Big Brothers Big Sisters of Southwest Louisiana has ...
(Date:5/4/2016)... , ... May 04, 2016 , ... May kicked off ... people across the United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as ... advice and focus on skin safety and health now and in the future. , ...
(Date:5/4/2016)... San Diego, California (PRWEB) , ... May 04, ... ... unique, wearable technology that is transforming breastfeeding for nursing mothers. The company’s patented ... milk intake while breastfeeding. Today, the company announced that the technology is now ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 2016  Specialty Silicone Fabricators is offering teachers ... a cleanroom works. The free visual aid provides ... technology. Chris Mazelin , ... SSF enthusiastically supports the Science, Technology, Engineering and ... next generation of innovators. We want to provide ...
(Date:5/3/2016)... PROVO, Utah , May 3, 2016  Forté Elements, LLC (Forté) is excited ... use nutritional products that address the nutritional needs of recovery for a variety of ... its products. Photo - http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/3/2016)... , May 3, 2016 ... heute bekannt, dass sie einen entscheidenden Meilenstein ... haben: Ein Aufruf zum Handeln, um Patientenresultate ... Veröffentlichung trägt zu Fortschritten im Verständnis der ... hervor, ein Bewusstsein für Hepatische Enzephalopathie in ...
Breaking Medicine Technology: